GlassScriptPhysician profile
Irakli Mania
NPI 1871778126
$969.63
in general payments reported to CMS, 2019-2025
20 companies · $93.03 in 2025
The $93.03 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $26.74 · 2021: $93.49 · 2022: $219 · 2023: $100 · 2024: $65.44 · 2025: $93.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $258.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $135.31 | 2019-2023 | Invega Trinza, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $130.77 | 2021-2023 | Austedo Xr |
| Abbvie INC. | $101.84 | 2022-2025 | |
| Indivior INC. | $86.47 | 2019-2024 | Sublocade |
| Vanda Pharmaceuticals INC. | $85.45 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $52.31 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $49.72 | 2023-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $46.22 | 2019 | |
| Ironshore Pharmaceuticals INC. | $38.35 | 2019-2022 | |
| Alkermes, INC. | $36.56 | 2021-2022 | |
| Neuronetics, INC. | $36.25 | 2022 | |
| Lundbeck LLC | $32.55 | 2019 | |
| Janssen Scientific Affairs, LLC | $31.92 | 2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $19.55 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $17.81 | 2023 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.97 | 2019 | |
| Neos Therapeutics, LP | $13.09 | 2019 | |
| Merck Sharp & Dohme LLC | $12.57 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irakli Mania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.